Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19275203 | 5T4 BINDING POLYPEPTIDES AND USES THEREOF | July 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 18099765 | PYRIDINIUM SALTS, METHODS OF MAKING, AND METHODS OF USE | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18082871 | TREATMENT OF RESPIRATORY VIRUS INFECTION BY MODULATION OF THE N-GLYCOSYLATION PATHWAY | December 2022 | November 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17937428 | IMMUNOCYTOKINE CONTAINING IL-21R MUTEIN | September 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17944604 | METHODS AND USE FOR BIOENGINEERING ENUCLEATED CELLS | September 2022 | December 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17822019 | METHODS FOR TREATING ANOREXIA NERVOSA AND RELATED CONDITIONS BY ADMINISTERING A LEPTIN RECEPTOR AGONIST | August 2022 | March 2026 | Allow | 42 | 2 | 0 | Yes | No |
| 17880141 | METHODS AND USE FOR BIOENGINEERING ENUCLEATED CELLS | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17777977 | Prame TCR Receptors And Uses Thereof | May 2022 | January 2026 | Allow | 44 | 2 | 0 | No | No |
| 17771192 | METHODS OF ADMINISTRATION OF IL-2 RECEPTOR AGONISTS | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17766746 | COMPOSITION COMPRISING INHIBITOR AGAINST EXPRESSION OF EXOSOMAL PD-L1 AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT | April 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17280239 | ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION | March 2021 | June 2025 | Allow | 50 | 1 | 0 | No | No |
| 17042610 | IL-2 Conjugates | September 2020 | October 2025 | Allow | 60 | 3 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner GURLEY, JAMI MICHELLE works in Art Unit 1647 and has examined 2 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner GURLEY, JAMI MICHELLE's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by GURLEY, JAMI MICHELLE receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GURLEY, JAMI MICHELLE is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by GURLEY, JAMI MICHELLE. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.